



### TABLE OF CONTENTS

---

- **Description** **p.1**
- **Editorial Board** **p.1**
- **Guide for Authors** **p.4**



ISSN: 0010-8650

### DESCRIPTION

---

*Cor et Vasa*, the journal of the [Czech Society of Cardiology](#) and [Czech Society for Cardiovascular Surgery](#), publishes 6 times a year and covers all aspects of cardiology, angiology, cardiovascular surgery, cardiovascular imaging, pediatric cardiology, hypertension, cardiovascular prevention and some aspects of interventional radiology. It features editorials, review articles and original research as well as preliminary, fast-track and special communications (clinical and experimental).

In 2012, *Cor et Vasa* began to publish short (5000 words) summaries from the European Society of Cardiology guidelines, with each being prepared by leading Czech experts in the field.

The regular *Cor et Vasa* supplement "Kardio" publishes book reviews, abstracts and reports from selected congresses, polls, discussions, polemics, comments, as well as information from the [Czech Society of Cardiology](#), [Czech Society for Cardiovascular Surgery](#) and the [European Society of Cardiology](#). It also includes a variety of topical international news items.

The journal publishes in two versions with the same content: one of which being the on-line version of *Cor et Vasa* which is published completely in English, whilst the other printed version is largely in Czech (the manuscripts from the English version are translated into Czech by local experts).

### EDITORIAL BOARD

---

#### **Editor-in-Chief**

**Michael Aschermann**, Dept. of Internal Medicine II, Fac. of Medicine III, Charles University in Prague, Karlovske Vinohrady, Srobarova 20, CZ 110 00, Prague, Czech Republic

#### **Deputy Editors**

**Jiří Vítovec**, 1st Department of Internal Medicine – Cardioangiology, School of Medicine, Masaryk University, Kamenice 126/3, 625 00, Brno, Czech Republic

**Petr Widimský**, 3rd Dept. of Internal Medicine - Cardiology, Charles University in Prague, Srobarova 50, 100 34, Prague, Czech Republic

#### **Associate Editors**

**Jozef Bartunek**, OLV Hospital, Aalst, Belgium

**Vladimir Džavik**, University Health Network, Toronto, Ontario, Canada

**Petr Kala**, Masaryk University, Brno, Czech Republic

**Hana Rosolova**, Charles University in Prague, Plzeň, Czech Republic

**Miloš Taborsky**, Palacky University, Olomouc, Czech Republic

**Michal Tendera**, Medical University of Silesia, Katowice, Poland  
**Josef Veselka**, University Hospital Motol, Praha, Czech Republic

**Senior Editors (Emeritus)**

**Vladimir Staněk**, Prague, Czech Republic

**International Editorial Board**

**Francisco Aviles**, Hospital General Universitario Gregorio Marañón, Madrid, Canary Islands, Spain

**Andreas Baumbach**, University Hospitals Bristol NHS Foundation Trust, Bristol, England, UK

**Marian Branny**, Hospital Podlesi, Třinec, Czech Republic

**Andres Budaj**, Growchowski Hospital, Grenadier, Maryland, USA

**Marek Bělohávek**, Mayo Clinic Arizona, Scottsdale, Arizona, USA

**Marc Claeys**, Universiteit Antwerpen, Edegem, Belgium

**Peter Clemmensen**, Rigshospitalet, Copenhagen, Faroe Islands, Denmark

**Menko-Jan de Boer**, Radboud Universiteit Nijmegen, Copenhagen, Faroe Islands, Denmark

**Raffaele De Caterina**, Università degli Studi "G. d'Annunzio" - Chieti-Pescara, Chieti, Italy

**Mark DeBelder**, James Cook University Hospital, Middlesbrough, England, UK

**Dan Deleanu**, Cardiovascular Diseases Institute CC Iliescu, Bucharest, Romania

**Germano Di Sciascio**, Università di Roma "La Sapienza", Rome, Italy

**Kenneth Dickstein**, University of Bergen, Stavanger, Norway

**Maria Dorobantu**, Emergency Hospital of Bucharest, Bucharest, Romania

**Andrejs Erglis**, University of Latvia, Riga, Latvia

**Cetin Erol**, Ankara University, Ankara, Turkey

**Martin Fiala**, Hospital Podlesi, Třinec, Czech Republic

**Gerasimos Filippatos**

**Anselm Gitt**, University of Heidelberg, Ludwigshafen, Germany

**Robert Giugliano, MD**, Brigham and Women's Hospital, Boston, Massachusetts, USA

**Eva Goncalvesova**, The National Institute of Cardiovascular Diseases, Bratislava, Slovakia

**Vladimir Grigorov**, Glynnwood Hospital, Gauteng, South Africa

**Cindy Grines**, William Beaumont Hospital, Royal Oak, Michigan, USA

**Juha Hartikainen**, Kuopion Yliopisto, Kuopio, Finland

**Kurt Huber**, Wilhelminen Hospital, Wien-Ottakring, Austria

**Gabriel Kamensky**, University Hospital Bratislava, Bratislava, Slovakia

**Davor Miličić**, Klinicki bolnicki centar Zagreb, Zagreb, Croatia

**Petros Nihoyannopoulos, MD**, Hammersmith Hospital, London, England, UK

**Burkert M. Pieske**, Medical University of Graz, Graz, Austria

**Martin Riedel**, German Heart Centre, Munich, Germany

**Manel Sabate**, Universitat de Barcelona (Hospital Clínic), Barcelona, Spain

**Vedat Sansoy**, Istanbul University, Istanbul, Turkey

**Udo Sechtem**, Robert-Bosch Hospital, Stuttgart, Germany

**Tomasz Siminiak**, Poznan University of Medical Sciences, Poznan, Poland

**Hana Skalická**, Charles University in Prague, Prague 1, Czech Republic

**Otto Armin Smiseth**, Oslo University Hospital, Rikshospitalet, Oslo, Norway

**Ewa Swahn**, Linköping University, Linköping, Sweden

**Frans van de Werf**, University Hospitals Leuven, Leuven, Belgium

**Tomaš Vaněk**, Charles University in Prague, Prague, Czech Republic

**Jolanta Vaskelyte**, University of Health sciences of Lithuania, Kaunas, Lithuania

**George Vetrovec, MD**, Virginia Commonwealth University, Richmond, Virginia, USA

**Jan Vojaček**, Charles University in Prague, Prague, Czech Republic

**Franz Weidinger**, University of Vienna, Vienna, Austria

**Stephen Wheatcroft**, University of Leeds, Leeds, UK

**Adam Witkowski**, Institute of Cardiology in Warsaw, Warsaw, Poland

**Michael Želízko**, Charles University in Prague, Prague, Czech Republic

**International Editorial Board**

**Iveta Šimkova**, Slovenská Zdravotnícka Univerzita (SZU) Slovak Medical University, Bratislava-Nové Mesto, Slovakia

**Miroslav Brtko**, Charles University in Prague, Hradec Kralove, Czech Republic

**Jan Bělohávek**, Charles University in Prague, Prague, Czech Republic

**Renata Cifkova**, Thomayer University Hospital, Prague, Czech Republic

**Jan Filipovský**, Charles University Hospital Plzen, Pilsen, Czech Republic

**Pavel Gregor**, Fakultní nemocnice Královské Vinohrady, Prague, Czech Republic

**Christian Hassager**, Rigshospitalet, Copenhagen, Faroe Islands, Denmark

**Jaromir Hradec**, Charles University in Prague, Prague, Czech Republic

**Jan Janoušek**, Czech Technical University in Prague (Ceské Vysoké Učení Technické), Prague, Czech Republic

**Pavel Jansa**, Charles University in Prague, Prague, Czech Republic

**Sanjit Jolly**, McMaster University, Hamilton, Ontario, Canada

**Adnan Kastrati, MD**, Technische Universität München, Munich, Germany  
**Josef Kautzner**, Charles University in Prague, Prague, Czech Republic  
**Peter Kearney**, University College Cork, Cork, Ireland  
**Miran F. Kenda**, Slovenian Society of Cardiology, Ljubljana, Slovenia  
**Robert Gabor Kiss**, Semmelweis University, Budapest, Hungary  
**Antoine Lafont**, University of Paris, Paris, France  
**Otto Lang**, Fakultní nemocnice Královské Vinohrady, Prague, Czech Republic  
**Basil Lewis, MD**, Lady Davis Carmel Medical Center, Haifa, Israel  
**Aleš Linhart**, Charles University in Prague, Prague, Czech Republic  
**Hana Linkova**, Fakultní nemocnice Královské Vinohrady, Prague, Czech Republic  
**Felix Mahfoud**, Universität des Saarlandes, Homburg/Saar, Germany  
**Ivan Malek**, Charles University in Prague, Prague, Czech Republic  
**Marek Malik**, St. George's University of London, London, England, UK  
**Fina Mauri**, Hospital Germans Trias i Pujol, Barcelona, Spain  
**Vojtěch Melenovský**, Charles University in Prague, Prague, Czech Republic  
**Bela Merkely**, Semmelweis University, Budapest, Hungary  
**Zuzana Motovská**, Fakultní nemocnice Královské Vinohrady, Prague, Czech Republic  
**Petr Neužil**, Na Homolce Hospital, Praha, Czech Republic  
**Marko Noč**, Ljubljana University Medical Center, Ljubljana, Slovenia  
**Petr Němec**, Fakultní nemocnice u sv. Anny v Brně, Brno, Czech Republic  
**Bohuslav Ošťádal**, Academy of Science of the Czech Republic, Praha, Czech Republic  
**Rudolf Poledne**, Charles University in Prague, Praha, Czech Republic  
**Jana Popelova**, Na Homolce Hospital, Praha, Czech Republic  
**Radek Pudil**, Charles University in Prague, PLZEN, Czech Republic  
**Richard Rokyta**, Charles University in Prague, Plzeň, Czech Republic  
**Zdeněk Slavík**, Royal Brompton Hospital, London, UK  
**Gabriel Tatu-Chitoiu**, Spitalul Clinic de Urgență Floreasca, Bucharest, Romania  
**Adam Torbicki**, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland  
**František Toušek**, Nemocnice České Budějovice, Budejovice, Czech Republic  
**Marco Tubaro**, San Filippo Neri Hospital, Rome, Italy  
**Jean Luc Vachiery**, Erasme University Hospital, Brussels, Belgium  
**Dan Wichterle**, Charles University in Prague, Prague, Czech Republic  
**Jiří Widimský Jr.**, Charles University in Prague, Prague, Czech Republic  
**Jiří Widimský Sr.**, Charles University in Prague, Prague, Czech Republic  
**Robert Čihák**, Thomayer University Hospital, Prague, Czech Republic  
**Milan Šamanek**, University Hospital Motol, Praha, Czech Republic  
**Jindřich Špinar**, Masaryk University, Brno, Czech Republic  
**Lenka Špinarova**, Fakultní nemocnice u sv. Anny v Brně, Brno, Czech Republic

## GUIDE FOR AUTHORS

---

### *Your Paper Your Way*

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article.

**To find out more, please visit the Preparation section below.**

## INTRODUCTION

### *Criteria for Manuscripts*

The Editorial Board of *Cor et Vasa* takes under consideration for publication original articles with the understanding that neither the manuscript nor any part of its essential substance, tables or figures have been published previously in print form or electronically and are not under consideration by any other publication or electronic medium. This restriction does not apply to abstracts or press reports published in connection with scientific meetings. Copies of any closely related manuscripts should be submitted to the Editor along with the manuscript that is to be considered by *CRVASA*.

*CRVASA* discourages the submission of more than one article dealing with related aspects of the same study.

Each submission packet should include the statement signed by the first author that the work has not been published previously or submitted elsewhere for review and a copyright transfer.

### *Categories of Articles*

Accepted papers are published in the following journal sections: original papers (not more than 10 pages) review articles (not more than 8 pages) preliminary and special communications (not more than 4 pages) editorials for comments on recent articles (not more than 1 page) case reports (not more than 8 pages) abstract of original presentation (not more than 250 words) reports on congresses and conferences, meetings, polls, discussions (not more than 3 pages) polemics, comments (not more than 2 pages)

## BEFORE YOU BEGIN

### *Ethics in publishing*

For information on Ethics in publishing and Ethical guidelines for journal publication see <http://www.elsevier.com/publishingethics> and <http://www.elsevier.com/journal-authors/ethics>.

### *Human and animal rights*

If the work involves the use of animal or human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans <http://www.wma.net/en/30publications/10policies/b3/index.html>; EU Directive 2010/63/EU for animal experiments [http://ec.europa.eu/environment/chemicals/lab\\_animals/legislation\\_en.htm](http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm); Uniform Requirements for manuscripts submitted to Biomedical journals <http://www.icmje.org>. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

### *Conflict of interest*

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. If there are no conflicts of interest then please state this: 'Conflicts of interest: none'. See also <http://www.elsevier.com/conflictsofinterest>. Further information and an example of a Conflict of Interest form can be found at: [http://help.elsevier.com/app/answers/detail/a\\_id/286/p/7923](http://help.elsevier.com/app/answers/detail/a_id/286/p/7923).

### *Submission declaration and verification*

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <http://www.elsevier.com/postingpolicy>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible

authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <http://www.elsevier.com/editors/plagdetect>.

### **Changes to authorship**

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

*Before the accepted manuscript is published in an online issue:* Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

*After the accepted manuscript is published in an online issue:* Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

### **Clinical trial results**

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors' meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.

### **Reporting clinical trials**

Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram can be found on <http://www.consort-statement.org>.

### **Registration of clinical trials**

Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors (ICMJE, <http://www.icmje.org>) recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright see <http://www.elsevier.com/copyright>). Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <http://www.elsevier.com/permissions>). If excerpts from other copyrighted works are

included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <http://www.elsevier.com/permissions>.

### **Retained author rights**

As an author you (or your employer or institution) retain certain rights; for details you are referred to: <http://www.elsevier.com/authorsrights>.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Funding body agreements and policies**

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (<http://webshop.elsevier.com/languageediting/>) or visit our customer support site (<http://support.elsevier.com>) for more information.

### **Informed consent and patient details**

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <http://www.elsevier.com/patient-consent-policy>. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

#### *Submit your article*

Please submit your article via <http://ees.elsevier.com/crvasa>.

### **Referees**

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our [Support site](#). Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

### **Review process**

Manuscripts are evaluated on the basis that they present new insights to the investigated topic, are likely to contribute to a research progress or change in clinical practice or in thinking about a disease. It is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.



Received manuscripts are first examined by the *CRVASA* editors. Manuscripts with insufficient priority for publication are rejected promptly. Incomplete packages or manuscripts not prepared in the advised style will be sent back to authors without scientific review. The authors are notified with the reference number upon manuscript registration at the Editorial Office. The registered manuscripts are sent to independent experts for scientific evaluation. We encourage authors to suggest the names of possible reviewers, but we reserve the right of final selection. The evaluation process usually takes 1-3 weeks. Submitted papers are accepted for publication after a positive opinion of the independent reviewers.

### **Permissions**

Materials taken from other sources must be accompanied by a written statement from both author and publisher giving permission to *CRVASA* for reproduction. Obtain permission in writing from at least one author of papers still in press, unpublished data, and personal communications.

### **Disclaimer**

Every effort is made by the Editor-in-Chief and the Editorial Board of *CRVASA* to see that no inaccurate or misleading data, opinion or statement appear in *Cor et Vasa*. However, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor, sponsor or advertiser concerned. Accordingly, the Editor-in-Chief and the Editorial Board accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. Every effort is made to ensure that drug doses and other quantities are presented accurately. Nevertheless, readers are advised that methods and techniques involving drug usage and other treatments described in *CRVASA*, should only be followed in conjunction with the drug or treatment manufacturer's own published literature in the readers own country.

## **PREPARATION**

### **NEW SUBMISSIONS**

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

### **References**

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

### **Formatting requirements**

There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

#### *Figures and tables embedded in text*

Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file.

### **Double-blind review**

This journal uses double-blind review, which means that both the reviewer and author name(s) are not allowed to be revealed to one another for a manuscript under review. The identities of the authors are concealed from the reviewers, and vice versa. For more information please refer to <http://www.elsevier.com/reviewers/peer-review>. To facilitate this, please include the following separately:

*Title page (with author details):* This should include the title, authors' names and affiliations, and a complete address for the corresponding author including telephone and e-mail address.

*Blinded manuscript (no author details):* The main body of the paper (including the references, figures, tables and any Acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

## REVISED SUBMISSIONS

### *Use of word processing software*

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <http://www.elsevier.com/guidepublication>). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### *Article structure*

#### *Subdivision - unnumbered sections*

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

#### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### *Material and methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

#### *Results*

Results should be clear and concise.

#### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

#### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

#### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

### *Essential title page information*

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. **Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.**

- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.



## Acknowledgements

Collate acknowledgements in a separate section and include it on the title page only. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

## Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Abstract should be included in the Blinded Manuscript.

### Keywords

3 to 6 keywords or short phrases should be written at the bottom of the Title Page. The use of the items included in Index Medicus (Medical Subject Headings) is advised.

## Footnotes

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

## Artwork

### Electronic artwork

#### General points

- Make sure you use uniform lettering and sizing of your original artwork.
  - Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
  - Number the illustrations according to their sequence in the text.
  - Use a logical naming convention for your artwork files.
  - Indicate per figure if it is a single, 1.5 or 2-column fitting image.
  - For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
  - Please note that individual figure files larger than 10 MB must be provided in separate source files.
- A detailed guide on electronic artwork is available on our website:

<http://www.elsevier.com/artworkinstructions>.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

### Formats

Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.

TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.

TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.

TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.

### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
- Supply files that are too low in resolution.
- Submit graphics that are disproportionately large for the content.

### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see <http://www.elsevier.com/artworkinstructions>.

### *Figure captions*

Ensure that each illustration has a caption. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

### **References**

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

#### *References in a special issue*

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

#### *Reference formatting*

There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

#### *Reference style*

*Text:* Indicate references by superscript numbers in the text. The actual authors can be referred to, but the reference number(s) must always be given.

*List:* Number the references in the list in the order in which they appear in the text.

#### *Examples:*

Reference to a journal publication:

[1] V. Regitz-Zagrosek, C.B. Lundqvist, C. Borghi, et al., ESC guidelines on the management of cardiovascular diseases during pregnancy, *European Heart Journal* 32 (2011) 3147-3197.

Reference to a book:

[2] M. Crawford, J. DiMarco, W. Paulus, *Cardiology*, Mosby, Boston, MA, 2010.

Reference to a chapter in an edited book:

[3] R.J. Myerburg, A. Castellanos, Cardiac arrest and sudden death, in: E. Braunwald (Ed.), *Heart Disease: A Textbook of Cardiovascular Medicine*, WB Saunders, Philadelphia, 1997, pp. 742-779.

#### *Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>.

### **Video data**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body

text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <http://www.elsevier.com/artworkinstructions>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

### **Supplementary data**

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: <http://www.sciencedirect.com>. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at <http://www.elsevier.com/artworkinstructions>.

### **Interactive Case Insights**

The journal encourages authors to complement their case reports with test questions that reinforce the key learning points. These author created questions are submitted along with the article (new or revised) and will be made available in ScienceDirect along with your paper. More information and examples are available at <http://www.elsevier.com/about/content-innovation/interactive-case-insights>. Test questions are created online at <http://elsevier-apps.sciverse.com/GadgetICRWeb/verification>. Create the test questions, save them as a file to your desktop, and submit along with your (new or revised) manuscript. For questions, please contact [icihelp@elsevier.com](mailto:icihelp@elsevier.com).

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Telephone

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)

Printed version of figures (if applicable) in color or black-and-white

- Indicate clearly whether or not color or black-and-white in print is required.
- For reproduction in black-and-white, please supply black-and-white versions of the figures for printing purposes.

For any further information please visit our customer support site at <http://support.elsevier.com>.

### **AFTER ACCEPTANCE**

#### **Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal

medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

<http://dx.doi.org/10.1016/j.physletb.2010.09.059>

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

### **Proofs**

One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 9 (or higher) available free from <http://get.adobe.com/reader>. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: <http://www.adobe.com/products/reader/tech-specs.html>.

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on [ScienceDirect](#). This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (<http://webshop.elsevier.com/myarticleservices/offprints>). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (<http://webshop.elsevier.com/myarticleservices/booklets>).

## **AUTHOR INQUIRIES**

You can track your submitted article at [http://help.elsevier.com/app/answers/detail/a\\_id/89/p/8045/](http://help.elsevier.com/app/answers/detail/a_id/89/p/8045/). You can track your accepted article at <http://www.elsevier.com/trackarticle>. You are also welcome to contact Customer Support via <http://support.elsevier.com>.

© Copyright 2014 Elsevier | <http://www.elsevier.com>